CareDx Announces Study Showing AlloSeq cfDNA Highly Accurate in Detecting Rejection in Organ Transplant Patients
Business Wire India AlloSeq cfDNA Consistent with Performance of Proven AlloSure Testing CareDx Brings Innovative Non-Invasive Transplant Monitoring to Patients Internationally with AlloSeq cfDNA CareDx, Inc. (Nasdaq: CDNA) – The…